232 filings
Page 4 of 12
8-K
rbs38f4i
17 Sep 20
Other Events
12:40pm
8-K
ylgj6hw r1q2jhsk
1 Sep 20
Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431
1:27pm
8-K
5zqgv
27 Aug 20
Other Events
11:19am
8-K
90b5ab9i
12 Aug 20
Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431’s Antiviral Properties
8:46am
8-K
taiutm41ymx2d3cop
5 Aug 20
Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial
9:18am
8-K
q20dev0fe i2
31 Jul 20
Submission of Matters to a Vote of Security Holders
12:00am
8-K
r15323
7 Jul 20
Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431
8:26am
8-K
1dt2znf 14
29 Jun 20
Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
12:00am
8-K
gmb1pg7d
22 Jun 20
Other Events
4:54pm
8-K
lzpit
15 Jun 20
Regulation FD Disclosure
9:22am
8-K
nwftw6 ez
10 Jun 20
Hepion Pharmaceuticals Welcomes Industry Veteran and Drug Development Expert, Dr. Peter Wijngaard, to its Board of Directors
5:04pm
8-K
lpe3e93mvkywd34
20 May 20
Hepion Pharmaceuticals Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
4:35pm
8-K
yroims6w0w
19 May 20
Regulation FD Disclosure
9:51pm
8-K
qsc pkgtx7jh
19 May 20
Other Events
8:12am
8-K
9pau22r40
14 May 20
Other Events
4:15pm
8-K
wfeo4fo4ma3tsol9y
17 Apr 20
Entry into a Material Definitive Agreement
4:05pm
8-K
7nyru22 41trc6v
30 Mar 20
Other Events
4:05pm
8-K
3ixu6ibv
27 Mar 20
Other Events
12:53pm
8-K
t0496r1nxyilj
12 Mar 20
Other Events
8:47am
8-K
pj5bgrm e5v3zio
11 Mar 20
Regulation FD Disclosure
4:05pm